Table 2. Univariate cox regression analysis of OS for patients with surgically resected pCCA in the training cohort.
Characteristics | Univariate analysis | ||
---|---|---|---|
HR | 95% CI | P value | |
Age (year) | <0.001*** | ||
<65 | Reference | ||
≥65 | 1.365 | 1.157–1.610 | <0.001*** |
Race | 0.598 | ||
White | Reference | ||
Black | 0.564 | ||
Other | 0.386 | ||
Sex | 0.502 | ||
Male | Reference | ||
Female | 0.502 | ||
Histology | 0.014* | ||
Adenocarcinoma and CCA | Reference | ||
Other | 0.744 | 0.587–0.942 | 0.014* |
Grade | 0.011* | ||
I | Reference | ||
II | 1.024 | 0.794–1.321 | 0.854 |
III | 1.352 | 1.037–1.762 | 0.026* |
IV | 0.934 | 0.43–2.029 | 0.863 |
AJCC T 6th stage | <0.001*** | ||
T1 | Reference | ||
T2 | 1.839 | 1.364–2.479 | <0.001*** |
T3 | 2.038 | 1.526–2.723 | <0.001*** |
T4 | 2.849 | 2.054–3.953 | <0.001*** |
AJCC M 8th stage | 0.005** | ||
M0 | Reference | ||
M1 | 1.713 | 1.179–2.489 | 0.005** |
AJCC N 7th stage | <0.001*** | ||
N0 | Reference | ||
N1 | 2.054 | 1.746–2.415 | <0.001*** |
N2 | 1.941 | 1.109–3.387 | 0.020* |
AJCC N 8th stage | <0.001*** | ||
N0 | Reference | ||
N1 | 1.844 | 1.55–2.194 | <0.001*** |
N2 | 2.921 | 2.3–3.71 | <0.001*** |
LODDS | <0.001*** | ||
LODDS1 | Reference | ||
LODDS2 | 1.826 | 1.518–2.198 | <0.001*** |
LODDS3 | 2.683 | 2.19–3.289 | <0.001*** |
LNR | <0.001*** | ||
LNR1 | Reference | ||
LNR2 | 1.871 | 1.532–2.285 | <0.001*** |
LNR3 | 2.443 | 2.017–2.96 | <0.001*** |
Radiation | 0.001** | ||
Yes | Reference | ||
No/unknown | 1.35 | 1.136–1.604 | 0.001** |
Chemotherapy | 0.004** | ||
Yes | Reference | ||
No/unknown | 1.262 | 1.075–1.481 | 0.004** |
Tumor size (cm) | <0.001*** | ||
<1.7 | Reference | ||
1.7–3.3 | 1.277 | 1.05–1.553 | 0.014 |
≥3.3 | 1.482 | 1.217–1.805 | <0.001*** |
*, P<0.05; **, P<0.01; ***, P<0.001. OS, overall survival; pCCA, perihilar cholangiocarcinoma; HR, hazard ratio; CI, confidence interval; CCA, cholangiocarcinoma; AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis; LODDS, log odds of positive lymph nodes; LNR, lymph node ratio.